Ischemix Elects Peter G. Milner, MD To Board Of Directors

MAYNARD, Mass.--(BUSINESS WIRE)--Ischemix, Inc., a clinical-stage pharmaceutical company focused on hospital-acquired kidney and cardiac injury, announced today that Peter G. Milner, MD has been elected to its Board of Directors. David A. DeWahl, Jr., President and CEO of Ischemix said "Dr. Milner's breadth of experience in pharmaceutical development and regulatory approvals will enhance the progress of our leading drug candidate and pipeline toward regulatory and clinical acceptance. His participation on our Board is a real vote of confidence in our drug candidates and approach."

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.